dose administered three times a week for 2 weeks.
Ceforanide is a new semisynthetic cephalosporin with a broad antibacterial spectrum (4, 7) . It is at least as active as other available cephalosporins against strains of Escherichia coli, Klebsiella, Proteus mirabilis, and Salmonella (1, 4, 7) . Comparative testing with cefamandole, cephalexin, cefoxitin, cephalothin, and cephapirin in vitro discloses that ceforanide is less potent against gram-positive cocci (1, 7) , but these observable differences may not be a practical problem in the clinical setting where in vitro mean inhibitory concentrations are exceeded severalfold (4 Interdialysis pharmacokinetics. Five inpatient volunteers were administered ceforanide, 750 mg/m2 of body surface area, in 150 ml of normal saline intravenously through the blood access site over 10 min starting 30 min before HD was completed. Forearm blood samples were obtained from the vascular access site at 1, 4, 12, 24, and 36 h after the end of HD, and just before the next HD session.
Pharmacokinetics during HD. Six outpatient volunteers received intravenous ceforanide, 750 mg/ m2 of body surface area, diluted in 100 ml of 5% dextrose and water and administered through the vascular access site over a 10-min period. HD Assay for ceforanide. Blood samples (4 ml) were collected in heparinized vacuum tubes and immediately placed on ice. Plasma was separated within 1 h and frozen until assayed. Dialysate was collected directly into sterile tubes and frozen immediately. Specimens were assayed by the agar plate cup bioassay method using Bacillus subtilis spore suspension (Difco Laboratories, Detroit, Mich.) in a nutrient agar overlay. Antibiotic-free human plasma was the diluent for all specimens except for the dialysate assay, in which antibiotic-free dialysate was used. These methods have been previously described (2, 3, 6) .
Kinetic calculations. The half-life (T1/2) of ceforanide was determined by the formula T1/2 -1n2/K.
where In is the natural logarithm and K. is the exponential elimination rate determined by the leastsquares method.
RESULTS
The T1/2 of ceforanide in patients with end stage renal disease was 19.1 ± 2.5 h in the interdialysis period (Table 2) . HD reduced the T1/2 to 5 ± 0.7 h in six other patients (Tables 1   and 3 ). Of the administred dose, 46% of ceforanide was recovered in the full volume of dialysate collected from one patient (no. 1).
Ceforanide, 1.5 g/m2 of body surface area, administered to six patients at the conclusion of 
